About this Research Topic
Lung cancer poses a significant global health burden, with limited efficacy of conventional treatments in advanced stages. However, the emergence of immunotherapy has revolutionized lung cancer management by leveraging the patient's immune system for targeted tumor eradication. Central to the success of immunotherapy are biomarkers, measurable indicators that provide insights into disease status and treatment response. Biomarkers such as programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), and microsatellite instability (MSI) have emerged as crucial predictive factors for immunotherapy outcomes. Understanding the intricate interplay between immunotherapy and these biomarkers is paramount for optimizing treatment strategies and improving patient outcomes. This Research Topic provides an academic overview of immunotherapy in lung cancer, emphasizing the significance of biomarkers in guiding therapeutic decisions and enhancing personalized treatment approaches. By elucidating these relationships, this research aims to contribute to the scientific understanding and clinical application of immunotherapy in lung cancer management.
Lung cancer remains a significant global health challenge, with limited treatment options and poor prognosis. Despite the remarkable success of immunotherapy in some lung cancer patients, there are still several critical challenges that need to be addressed. One major hurdle is the identification and validation of reliable biomarkers that can predict response to immunotherapy and guide treatment decisions. This Research Topic aims to tackle this problem by exploring the latest advances in understanding the role of biomarkers and immunotherapy for lung cancer. To achieve this objective, we will invite researchers from diverse disciplines including oncology, immunology, molecular biology, and bioinformatics to contribute their expertise. We encourage studies that investigate both established and emerging biomarkers associated with immunotherapy response in lung cancer patients. Significant progress has been made in recent years in identifying potential biomarkers for immunotherapy response in lung cancer, including PD-L1, TMB, and the presence of specific genetic alterations. By compiling and disseminating the latest research on immunotherapy and biomarkers for lung cancer, this Research Topic aims to foster collaborations, highlight recent advances, and stimulate further investigations in this rapidly evolving field.
Ultimately, our goal is to enhance the personalized treatment of lung cancer patients, improve response rates to immunotherapy, and optimize patient outcomes.
We aim to cover a wide range of themes within this field, encouraging contributors to address the following specific topics:
1. Identification and Validation of Biomarkers: Manuscripts focusing on the identification and validation of reliable biomarkers that can predict response to immunotherapy in lung cancer patients.
2. Biomarkers Associated with Treatment Response: Studies investigating established and emerging biomarkers associated with immunotherapy response in lung cancer patients, such as PD-L1 expression, tumor mutational burden (TMB), immune cell infiltrates, genetic alterations, and circulating biomarkers.
3. Mechanisms of Immunotherapy Resistance: Manuscripts exploring the mechanisms underlying resistance to immunotherapy in lung cancer, including the role of biomarkers in predicting and understanding treatment resistance.
4. Biomarker-Guided Treatment Decisions: Research examining how biomarkers can guide treatment decisions in lung cancer patients undergoing immunotherapy, including their impact on treatment stratification and personalized medicine approaches.
5. Novel Biomarker Discovery: Studies focused on the discovery of novel biomarkers associated with immunotherapy response in lung cancer, utilizing approaches like next-generation sequencing, immune profiling, and liquid biopsy techniques.
6. Translational Research and Clinical Applications: Manuscripts highlighting translational research efforts and clinical applications of biomarkers in the field of immunotherapy for lung cancer, including their utility in patient monitoring, prognosis, and therapeutic decision-making.
Types of Manuscripts of Interest: We welcome original research articles, reviews, systematic reviews/meta-analyses, perspectives, and opinion papers related to the scope of this Research Topic. Additionally, we encourage the submission of methodological papers that present innovative approaches for biomarker identification, validation, and application in the context of lung cancer immunotherapy. By addressing these themes and manuscript types, this Research Topic aims to provide a comprehensive overview of the latest advancements in immunotherapy and biomarkers for lung cancer. It will serve as a platform to disseminate cutting-edge research, foster collaboration, and facilitate the translation of scientific findings into clinical practice.
Please Note: Manuscripts based on re-analysis of pre-existing data collections will only be considered when including appropriate experimental validation or in the context of novel data analysis methodologies and verification through independent datasets.
Lung cancer remains a significant global health challenge, with limited treatment options and poor prognosis. Despite the remarkable success of immunotherapy in some lung cancer patients, there are still several critical challenges that need to be addressed. One major hurdle is the identification and validation of reliable biomarkers that can predict response to immunotherapy and guide treatment decisions. This Research Topic aims to tackle this problem by exploring the latest advances in understanding the role of biomarkers and immunotherapy for lung cancer. To achieve this objective, we will invite researchers from diverse disciplines including oncology, immunology, molecular biology, and bioinformatics to contribute their expertise. We encourage studies that investigate both established and emerging biomarkers associated with immunotherapy response in lung cancer patients. Significant progress has been made in recent years in identifying potential biomarkers for immunotherapy response in lung cancer, including PD-L1, TMB, and the presence of specific genetic alterations. By compiling and disseminating the latest research on immunotherapy and biomarkers for lung cancer, this Research Topic aims to foster collaborations, highlight recent advances, and stimulate further investigations in this rapidly evolving field.
Ultimately, our goal is to enhance the personalized treatment of lung cancer patients, improve response rates to immunotherapy, and optimize patient outcomes.
We aim to cover a wide range of themes within this field, encouraging contributors to address the following specific topics:
1. Identification and Validation of Biomarkers: Manuscripts focusing on the identification and validation of reliable biomarkers that can predict response to immunotherapy in lung cancer patients.
2. Biomarkers Associated with Treatment Response: Studies investigating established and emerging biomarkers associated with immunotherapy response in lung cancer patients, such as PD-L1 expression, tumor mutational burden (TMB), immune cell infiltrates, genetic alterations, and circulating biomarkers.
3. Mechanisms of Immunotherapy Resistance: Manuscripts exploring the mechanisms underlying resistance to immunotherapy in lung cancer, including the role of biomarkers in predicting and understanding treatment resistance.
4. Biomarker-Guided Treatment Decisions: Research examining how biomarkers can guide treatment decisions in lung cancer patients undergoing immunotherapy, including their impact on treatment stratification and personalized medicine approaches.
5. Novel Biomarker Discovery: Studies focused on the discovery of novel biomarkers associated with immunotherapy response in lung cancer, utilizing approaches like next-generation sequencing, immune profiling, and liquid biopsy techniques.
6. Translational Research and Clinical Applications: Manuscripts highlighting translational research efforts and clinical applications of biomarkers in the field of immunotherapy for lung cancer, including their utility in patient monitoring, prognosis, and therapeutic decision-making.
Types of Manuscripts of Interest: We welcome original research articles, reviews, systematic reviews/meta-analyses, perspectives, and opinion papers related to the scope of this Research Topic. Additionally, we encourage the submission of methodological papers that present innovative approaches for biomarker identification, validation, and application in the context of lung cancer immunotherapy. By addressing these themes and manuscript types, this Research Topic aims to provide a comprehensive overview of the latest advancements in immunotherapy and biomarkers for lung cancer. It will serve as a platform to disseminate cutting-edge research, foster collaboration, and facilitate the translation of scientific findings into clinical practice.
Please Note: Manuscripts based on re-analysis of pre-existing data collections will only be considered when including appropriate experimental validation or in the context of novel data analysis methodologies and verification through independent datasets.
Keywords: Immunotherapy, Biomarkers, Lung Cancer, Checkpoint Inhibitors, PD-L1, Tumor Mutational Burden, Genetic Alterations, Immune Profiling, Personalized Medicine.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
